Canada's VentriPoint Diagnostics Ltd. said the U.S. Food and Drug Administration granted market clearance for its VMS+ echocardiography system.
The VMS+ was approved for the 3D volumetric analysis of all four chambers of the heart using 2D ultrasound.
VentriPoint develops and sells diagnostic tools that monitor patients with heart disease.
